Celgene, Presage Biosciences deal

Presage partnered with Celgene to use Presage's technology to identify new drug combinations for solid tumors. Presage will receive $5 million up front in research funding and an $8 million equity investment. The biotech is also eligible for "substantial," undisclosed milestone payments. Presage's in vivo screening platform enables simultaneous comparison of up to four treatments within a single tumor in a live mouse via microdose bands. The partners declined to disclose additional details. ...